Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets the BCR‑ABL protein and is indicated for the treatment of chronic myeloid leukemia in both chronic and accelerated phases in adult patients.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, oncology centres and pharmacies worldwide while adhering to stringent quality and regulatory standards. The company leverages a global distribution network to meet the needs of healthcare providers across multiple regions.

Nilotinib is a tyrosine kinase inhibitor used in the management of chronic myeloid leukemia, acting on the BCR‑ABL signaling pathway. - Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves long‑term survival. - Chronic myeloid leukemia (accelerated phase): helps achieve hematologic and cytogenetic responses, slowing disease progression. - Philadelphia chromosome‑positive CML: provides targeted therapy for patients with the BCR‑ABL fusion gene.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash

Serious or Rare Side Effects: - QT interval prolongation and cardiac arrhythmias - Hepatic toxicity (elevated liver enzymes) - Severe neutropenia

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts regularly: detect neutropenia or thrombocytopenia early. - Assess liver function before and during therapy: watch for hepatic toxicity. - Perform ECG monitoring: identify QT prolongation risk. - Avoid use in patients with known hypersensitivity to nilotinib or its excipients. - Use caution in hepatic impairment: dose adjustment may be required. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nilotinib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nilotinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce nilotinib effectiveness. - Antacids containing aluminum or magnesium: decrease absorption of nilotinib. - Concomitant QT‑prolonging drugs (e.g., amiodarone, sotalol): heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may alter anticoagulant effect. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased statin levels. - Oral contraceptives: potential reduced efficacy.